Compare RNXT & POM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNXT | POM |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4M | 30.3M |
| IPO Year | 2021 | 2025 |
| Metric | RNXT | POM |
|---|---|---|
| Price | $0.93 | $0.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | 191.9K | ★ 476.3K |
| Earning Date | 03-30-2026 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $928,000.00 | ★ $51,210,721.00 |
| Revenue This Year | $2,795.35 | N/A |
| Revenue Next Year | $272.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.13 |
| 52 Week Low | $0.70 | $0.21 |
| 52 Week High | $1.45 | $6.43 |
| Indicator | RNXT | POM |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 27.86 |
| Support Level | $0.92 | $0.22 |
| Resistance Level | $1.08 | $0.25 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 23.81 | 40.91 |
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.